Feedback / Questions
enozertinib (ORIC-114) - ORIC Pharma, Voronoi
https://www.globenewswire.com/news-release/2025/12/05/3200427/0/en/ORIC-Pharmaceuticals-Presents-Potential-Best-in-Class-Profile-for-Enozertinib-with-Robust-Systemic-and-CNS-Activity-in-1L-and-Previously-Treated-NSCLC-Patients-with-EGFR-Atypical-M.html
Dec 4, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next